Clinical trial · Interventional
Effect of Transfer Energy Capacitive and Resistive Therapy on Palmar Fibromatosis
NCT07443371CI-TRIAL-00104377not yet recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The objective of the present study is to explore the effect of Transfer Energy Capacitive and Resistive Therapy (TECAR) therapy on pain, range of motion (ROM) and hand function in dupuytren's contracture patients (palmar fibromatosis).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Palmar Fibromatosis | Palmar Fibromatosis | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Traditional therapy | Other | — | UNRESOLVED |
| Transfer Energy Capacitive and Resistive (TECAR) therapy | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Transfer Energy Capacitive and Resistive (TECAR) therapy
- description
- The patients will receive Tecar therapy, in addition to traditional therapy for 6 weeks
- interventionNames
- Device: Transfer Energy Capacitive and Resistive (TECAR) therapy
- Other: Traditional therapy
- type
- ACTIVE_COMPARATOR
- label
- Traditional therapy group
- description
- The patients will receive traditional therapy only for 6 weeks .
- interventionNames
- Other: Traditional therapy
Primary outcomes (3)
- measure
- Active range of motion (ROM) assessment of metacarpophalangeal joint (MCP):
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 40 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Ages of patients will be ranged from 40 to 70 years. * Presence of palpable cords and/or digital contracture ≥ 20° at the metacarpophalengeal joint or Proximal interphalengeal joint joints . * Clinical diagnosis confirmed by a hand surgeon or relevant specialist. * All patients will enter the study having their informed consent Exclusion Criteria: * Patient with severe contracture \>30° or multiple digit involvement requiring surger. * History of surgical release (fasciotomy, fasciectomy) or collagenase injection in the affected hand. * Presence of infection, ulceration, or skin lesions on the treatment area. * Presence of pacemakers, metal implants, or other electronic implants in the treatment area. * Active cancer or tumor in the treatment region. * Pregnancy. * Conditions such as stroke, Parkinson's disease, or rheumatoid arthritis that may confound results. * Cognitive impairment, psychiatric illness, or other barriers to protocol adherence
References
Publications (0)
Data not yet available
No reference posted for this study.